Tables--Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 1. Table 1

Table 1. EGFR-TK Inhibitors

Generic Name	Trade Name [development name]	FDA-approved Indications	Dosage	Mechanism of Action
Gefitinib	Iressa™ [ZD1839]	Advanced NSCLC	250-500 mg PO daily	Inhibits the intracellular tyrosine kinase (TK) of epidermal growth factor receptor (EGFR), resulting in cell cycle arrest, apoptosis, and inhibition of angiogenesis and tumor cell invasion
Erlotinib	Tarceva™ [OSI-774]	NSCLC	150 mg PO daily
- -	Not marketed [CI-1033]	Not yet approved
Lapatinib	Not marketed [GW572016]	Not yet approved
- -	Not marketed [EKB-569]	Not yet approved

Abbreviations: EGFR-TK = epidermal growth factor receptor tyrosine kinase; FDA = Food and Drug Administration; NSCLC = non-small cell lung cancer; PO = per os (by mouth).

Return to Document